Auris Nasus Larynx最新文献

{"title":"C-C chemokine receptor 4 is a candidate for regulatory T-cell-depletion immunotherapy in differentiated thyroid cancer","authors":"Rui Sano ,&nbsp;Hiromu Nakamura ,&nbsp;Susumu Suzuki ,&nbsp;Daisuke Inukai ,&nbsp;Hiroki Okamoto ,&nbsp;Shunpei Yamanaka ,&nbsp;Taishi Takahara ,&nbsp;Akira Satou ,&nbsp;Yasushi Fujimoto ,&nbsp;Toyonori Tsuzuki ,&nbsp;Ryuzo Ueda ,&nbsp;Tetsuya Ogawa","doi":"10.1016/j.anl.2025.12.004","DOIUrl":"10.1016/j.anl.2025.12.004","url":null,"abstract":"<div><h3>Objective</h3><div>Immunotherapy using immune checkpoint inhibitors is a standard treatment option for many types of malignancies but is not effective for differentiated thyroid cancer (DTC). Regulatory T-cells (Tregs), which are one of the main suppressive factors in the tumor microenvironment, are another important target for immunotherapy. This study investigated the characteristics of Tregs in DTC with the aim of further developing immunotherapy.</div></div><div><h3>Methods</h3><div>Peripheral blood lymphocytes (PBLs) and tumor-infiltrating lymphocytes (TILs) were obtained from 12 patients with DTC and 12 patients with goiter (benign control group) who underwent primary surgery between February 2017 and September 2022. Flow cytometry analyses were performed for CD4, CD45RA, FOXP3, C<img>C chemokine receptor 4 (CCR4; a candidate Treg-targeting molecule), and immune checkpoint molecules in order to characterize the features of Tregs.</div></div><div><h3>Results</h3><div>In the DTC patients, age ranged from 39 to 84 years, and the male:female ratio was 7:5. Pathological staging was pT1 or pT2 in 4 patients, pT3 in 8, pN0 in 5, and pN1 in 7, and extrathyroidal extension was observed in 5 patients. Effector Treg (eTreg) frequency in CD4⁺ <em>T</em>-cells in TILs and PBLs was significantly higher in DTC than in goiter. Extrathyroidal extension was associated with a higher eTreg frequency in TILs. A positive correlation was found between eTreg frequency and the expression of immune checkpoint molecules (PD-1, TIM3, GITR, and OX40) on eTregs in TILs from DTC patients. These findings suggest that Tregs are activated in DTC and are important in the creation of an immunosuppressive microenvironment. In addition, the mean positive rate (±standard deviation) of CCR4 on eTregs was high in PBLs (95.8 % ± 3.8 %) and TILs (92.8 % ± 9.8 %) from DTC patients, suggesting that CCR4 is a potential target for eTreg-depletion immunotherapy for DTC.</div></div><div><h3>Conclusion</h3><div>Tregs were increased and activated in DTC tumor tissue, indicating that they play an important role in creating an immunosuppressive microenvironment in DTC. The results suggest that eTreg-depletion immunotherapy using an anti-CCR4 antibody (mogamulizumab) might be effective for treating DTC.</div></div>","PeriodicalId":55627,"journal":{"name":"Auris Nasus Larynx","volume":"53 1","pages":"Pages 27-34"},"PeriodicalIF":1.5,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145745818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subtotal petrosectomy for extensive cholesteatoma: A case series from Japan","authors":"Hiroshi Sakaida,&nbsp;Kazuhiko Takeuchi","doi":"10.1016/j.anl.2025.12.001","DOIUrl":"10.1016/j.anl.2025.12.001","url":null,"abstract":"<div><h3>Objective</h3><div>Subtotal petrosectomy (STP) is a standard procedure for intractable middle ear disease in Western countries, but reports from Japan are scarce. This report describes the clinical experience, patient characteristics, and surgical outcomes of STP at a tertiary center in Japan.</div></div><div><h3>Methods</h3><div>We retrospectively reviewed the medical records of all patients who underwent STP in our department between January 2018 and April 2022. We analyzed patient demographics, underlying pathology, preoperative findings, postoperative complications, and the cholesteatoma recurrence rate.</div></div><div><h3>Results</h3><div>The cohort included 11 patients (7 male, 4 female) with a median age of 75 years. The primary indication was extensive cholesteatoma (11 cases), which was often complicated by dural exposure (6 cases) and labyrinthine fistula (6 cases). Postoperative complications occurred in 1 patient (9 %), who developed a fistula at the blind sac closure site. There were no instances of postoperative facial nerve palsy or inner ear complications. MRI surveillance revealed a residual cholesteatoma recurrence rate of 27 % (3 cases).</div></div><div><h3>Conclusion</h3><div>STP is an option for managing extensive primary cholesteatoma where hearing reconstruction is not feasible, particularly in the elderly population. However, the risk of residual cholesteatoma is significant, as evidenced by a 27 % recurrence rate in this series, and careful surgical indication is essential to avoid potential over-indication. This finding highlights the critical importance of meticulous surgical technique and rigorous postoperative imaging surveillance to ensure long-term disease control.</div></div>","PeriodicalId":55627,"journal":{"name":"Auris Nasus Larynx","volume":"53 1","pages":"Pages 13-18"},"PeriodicalIF":1.5,"publicationDate":"2025-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145716756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intracranial antitumor efficacy of combination treatment with encorafenib plus binimetinib in BRAF V600E-mutated anaplastic thyroid carcinoma","authors":"Ryutaro Onaga ,&nbsp;Tomohiro Enokida ,&nbsp;Toshifumi Tomioka ,&nbsp;Shingo Sakashita ,&nbsp;Masanobu Sato ,&nbsp;Nobukazu Tanaka ,&nbsp;Yuta Hoshi ,&nbsp;Takuma Kishida ,&nbsp;Ryo Kuboki ,&nbsp;Takao Fujisawa ,&nbsp;Susumu Okano ,&nbsp;Kazuto Matsuura ,&nbsp;Makoto Tahara","doi":"10.1016/j.anl.2025.11.007","DOIUrl":"10.1016/j.anl.2025.11.007","url":null,"abstract":"<div><div>The intracranial antitumor efficacy of combination therapy with BRAF and MEK inhibitors in <em>BRAF</em>-mutated thyroid cancer has not been reported. Here, we describe a case of anaplastic thyroid cancer harboring <em>BRAF</em> V600E mutation with brain metastases which was treated with encorafenib plus binimetinib. The patient was initially diagnosed with T4bN1bM1 and experienced disease progression following surgery and lenvatinib treatment. Encorafenib plus binimetinib was initiated as second-line treatment seven months after the surgery. After achieving sustained disease stabilization, a solitary asymptomatic brain metastasis was detected following a three-week interruption due to COVID-19 infection. The lesion shrank after only two weeks of resumed encorafenib plus binimetinib, and additional stereotactic radiosurgery was performed without significant adverse events. This case suggests that the combination of BRAF and MEK inhibitors may be a viable treatment option for brain metastasis in <em>BRAF</em>-mutated thyroid cancer, despite general prioritization of local treatments. In addition, encorafenib plus binimetinib treatment may suppress the growth of microscopic metastasis. This possibility is supported by reliable evidence for the use of BRAF plus MEK inhibitor for brain metastasis from <em>BRAF</em>-mutated malignant melanoma. We conclude that encorafenib plus binimetinib treatment for brain metastasis from <em>BRAF</em>-mutated thyroid cancer is a safe and effective treatment choice.</div></div>","PeriodicalId":55627,"journal":{"name":"Auris Nasus Larynx","volume":"53 1","pages":"Pages 7-12"},"PeriodicalIF":1.5,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145688686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Authors' reply: Comments on \"Physical therapy for peripheral facial palsy: A systematic review and meta-analysis\".","authors":"Haruki Nakano, Takashi Fujiwara, Yasushi Tsujimoto, Naohito Morishima, Takashi Kasahara, Misato Ameya, Keita Tachibana, Shota Sanada, Saori Toufukuji, Naohito Hato","doi":"10.1016/j.anl.2025.11.002","DOIUrl":"https://doi.org/10.1016/j.anl.2025.11.002","url":null,"abstract":"","PeriodicalId":55627,"journal":{"name":"Auris Nasus Larynx","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145662957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic impact of sarcopenia and systemic inflammation in head and neck cancer patients treated with immune checkpoint inhibitors","authors":"Ken Kasahara ,&nbsp;Takeyuki Kono ,&nbsp;Yoichiro Sato ,&nbsp;Keisuke Okubo ,&nbsp;Ayaka Sasaki ,&nbsp;Ko Hentona ,&nbsp;Yutaro Mokudai ,&nbsp;Keigo Oguchi ,&nbsp;Motoki Izawa ,&nbsp;Seiichi Shinden ,&nbsp;Hiroyuki Ozawa","doi":"10.1016/j.anl.2025.11.006","DOIUrl":"10.1016/j.anl.2025.11.006","url":null,"abstract":"<div><h3>Objective</h3><div>Sarcopenia and systemic inflammatory markers predict prognosis in various cancers, including head and neck cancer (HNC) treated with surgery or chemoradiotherapy. Their significance in patients receiving immune checkpoint inhibitors (ICIs), however, remains unclear. This study aims to determine whether skeletal muscle loss and systemic inflammation influence treatment response and survival in ICI-treated HNC, and whether composite indices provide prognostic value.</div></div><div><h3>Methods</h3><div>A retrospective cohort of 179 patients with histologically confirmed recurrent or metastatic (R/M) HNC who received ICI therapy between April 2017 and July 2024 was analyzed. Sarcopenia was assessed using the lumbar skeletal muscle index (LSMI), calculated from cervical CT images. Inflammatory markers such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) were derived from pre-treatment blood samples. Overall survival (OS) and progression-free survival (PFS) were evaluated using Kaplan–Meier estimates, and prognostic factors were identified through Cox regression analysis.</div></div><div><h3>Results</h3><div>Among the 179 patients, 98 (54.7%) were classified as sarcopenic. These patients had significantly shorter median OS compared to non-sarcopenic patients (12.1 vs. 39.8 months; p &lt; 0.001). Univariate analysis identified sarcopenia, BMI, NLR, and PLR as significant predictors of OS. However, multivariate Cox analysis revealed that only sarcopenia remained an independent prognostic factor for both OS (HR 1.94; 95% CI: 1.15–3.27; p = 0.013) and PFS (HR 1.92; 95% CI: 1.33–2.75; p &lt; 0.001). Inflammatory markers and their composite indices failed to retain prognostic significance in adjusted models.</div></div><div><h3>Conclusion</h3><div>Sarcopenia independently predicts poor survival outcomes in patients with R/M HNC undergoing ICI therapy, whereas conventional inflammatory markers such as NLR, PLR, and LMR, alone or in combination with sarcopenia, lack independent prognostic value. Routine pre-treatment evaluation of skeletal muscle mass using CT imaging may offer a practical and effective tool for patient risk stratification.</div></div>","PeriodicalId":55627,"journal":{"name":"Auris Nasus Larynx","volume":"53 1","pages":"Pages 1-6"},"PeriodicalIF":1.5,"publicationDate":"2025-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145625061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comments on \"Physical therapy for peripheral facial palsy: A systematic review and meta-analysis\".","authors":"Run-Cheng Wang, Li-Hua Xuan","doi":"10.1016/j.anl.2025.11.001","DOIUrl":"https://doi.org/10.1016/j.anl.2025.11.001","url":null,"abstract":"","PeriodicalId":55627,"journal":{"name":"Auris Nasus Larynx","volume":" ","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145589672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trial for developing a reference extract for future standardization of Japanese cypress pollen extracts","authors":"Kengo Kanai ,&nbsp;Aiko Oka ,&nbsp;Hideaki Kouzaki ,&nbsp;Kento Kawakita ,&nbsp;Takuya Murao ,&nbsp;Takeshi Shimizu ,&nbsp;Takaya Higaki ,&nbsp;Aya Murai ,&nbsp;Mizuo Ando ,&nbsp;Kojiro Hirano ,&nbsp;Isao Suzaki ,&nbsp;Hitome Kobayashi ,&nbsp;Minoru Gotoh ,&nbsp;Kimihiro Okubo ,&nbsp;Mitsuhiro Okano","doi":"10.1016/j.anl.2025.10.001","DOIUrl":"10.1016/j.anl.2025.10.001","url":null,"abstract":"<div><h3>Objective</h3><div>Japanese cedar pollinosis (JCP) is the most prevalent seasonal allergic rhinitis in Japan. Many JCP patients are also sensitized to Japanese cypress pollen (JCyP), and their symptoms become exacerbated and prolonged during the JCyP dispersal period after JCP. To date, there have been no reports on the development of JCyP-specific allergen immunotherapy. For the future development of a JCyP-specific skin test and immunotherapy, we sought to develop a reference extract for future standardization of JCyP extract determined by the average threshold dilution eliciting a positive response in the intradermal skin test.</div></div><div><h3>Methods</h3><div>A 1:20 antigen extract (Lot AA) was prepared from JCyP grains by the glycerin extraction method. The protein and allergen concentrations in the extract were determined. After confirming its safety, 3-fold serially diluted solutions of JCyP extract were prepared from Lot AA. The average threshold dilution eliciting a positive response in the intradermal skin test was determined among Japanese subjects with serum JCyP-specific IgE class of 2 or higher according to ImmunoCAP IgE assays or View39 IgE assays.</div></div><div><h3>Results</h3><div>The protein concentration in Lot AA was 4.7 mg/mL, and the allergen concentration was 18.8 μg/mL for Cha o 1 and 1.1 μg/mL for Cha o 3. In total, 85 individuals were registered for this study and finally, 55 subjects were left for the analysis. The threshold dilution for an intradermal reaction was 3⁶ in 32 individuals (58.2 %), 3⁷ in 8 individuals (14.6 %), 3⁸ in 4 individuals (7.3 %), and 3⁹ in 1 individual (1.8 %); no reaction was seen in 10 individuals (18.2 %). The average threshold dilution was 3^6.4, which is equivalent to a 1131-fold dilution. No serious adverse events were observed at any of the tested dilutions.</div></div><div><h3>Conclusion</h3><div>The results showed that Lot AA of JCyP extract exhibited <em>in vivo</em> allergic potency and was safe. Thus, it may be useful as a future standardized antigen of JCyP or a reference antigen for standardizing other JCyP extracts for the diagnosis and treatment of JCyP pollinosis.</div></div>","PeriodicalId":55627,"journal":{"name":"Auris Nasus Larynx","volume":"52 6","pages":"Pages 805-810"},"PeriodicalIF":1.5,"publicationDate":"2025-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145558256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Impact of hearing impairment in unilateral hearing loss: A multicenter study of standardized sound localization tests in Japan.” [Auris Nasus Larynx, Volume 52, Issue 6, December 2025, Pages 690-703]","authors":"Takashi Ishino ,&nbsp;Tadao Yoshida ,&nbsp;Satoshi Iwasaki ,&nbsp;Naoki Oishi ,&nbsp;Yusuke Matsuda ,&nbsp;Tetsuya Tono ,&nbsp;Kazuma Sugahara ,&nbsp;Hiroshi Yamazaki ,&nbsp;Sumito Jitsukawa ,&nbsp;Hiroshi Nakanishi ,&nbsp;Ryosuke Kitoh ,&nbsp;Takashi Sato ,&nbsp;Kazuki Nishida ,&nbsp;Takashi Oda ,&nbsp;Rikuto Fujita ,&nbsp;Tomohiro Kawasumi ,&nbsp;Chie Ishikawa ,&nbsp;Manabu Nishida ,&nbsp;Nobuyuki Chikuie ,&nbsp;Yuichiro Horibe ,&nbsp;Sachio Takeno","doi":"10.1016/j.anl.2025.10.012","DOIUrl":"10.1016/j.anl.2025.10.012","url":null,"abstract":"","PeriodicalId":55627,"journal":{"name":"Auris Nasus Larynx","volume":"52 6","pages":"Pages 803-804"},"PeriodicalIF":1.5,"publicationDate":"2025-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145551871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Salvage surgery following boron neutron capture therapy in a case of recurrent hypopharyngeal cancer after radiotherapy: Surgical and pathological insights","authors":"Akihisa Tanaka ,&nbsp;Kohtaro Eguchi ,&nbsp;Mitsuhiko Katoh ,&nbsp;Tatsuya Ito ,&nbsp;Azusa Sakai ,&nbsp;Toshihiko Sakai ,&nbsp;Chihiro Fushimi ,&nbsp;Go Omura ,&nbsp;Taisuke Mori ,&nbsp;Seiichi Yoshimoto","doi":"10.1016/j.anl.2025.10.013","DOIUrl":"10.1016/j.anl.2025.10.013","url":null,"abstract":"<div><div>Radiotherapy (RT) is a cornerstone management strategy for head and neck cancer (HNC); however, local recurrence often requires salvage surgery, which is associated with an elevated risk of complications, particularly in previously irradiated fields. Boron neutron capture therapy (BNCT) has broadened treatment options; however, the safety and feasibility of salvage surgery after BNCT remain unclear owing to the limited case number. Herein, we describe a rare case of hypopharyngeal squamous cell carcinoma initially treated with RT, followed by BNCT for local recurrence, and ultimately with successful salvage surgery. The patient experienced no significant intraoperative or postoperative complications, and has remained recurrence-free for three years while maintaining adequate activities of daily living. Histopathological examination revealed no abnormal fibrosis exceeding that typically observed following standard RT alone throughout the resected specimen. Instead, edematous changes predominated over fibrotic alterations exclusively within the tumor region, presumed to be most affected by BNCT, accompanied by strong expression of L-type amino acid transporter 1, a potential surrogate marker of BNCT indication, suggesting the tumor-specific therapeutic effect of BNCT. This is the first report of salvage surgery for an organ previously treated with RT and BNCT, which provides valuable clinical and histopathological insights into this condition.</div></div>","PeriodicalId":55627,"journal":{"name":"Auris Nasus Larynx","volume":"52 6","pages":"Pages 785-789"},"PeriodicalIF":1.5,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145520389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neck stiffness and its correlation with dysphagia after radiotherapy in head and neck cancer","authors":"Junki Ono ,&nbsp;Hideaki Nishi ,&nbsp;Sumie Takashima ,&nbsp;Shuntaro Soejima ,&nbsp;Ryo Toya ,&nbsp;Yoshihiko Kumai","doi":"10.1016/j.anl.2025.10.011","DOIUrl":"10.1016/j.anl.2025.10.011","url":null,"abstract":"<div><h3>Objective</h3><div>Dysphagia is one of the most significant adverse effects after radiotherapy (RT) for advanced head and neck cancer (HNC). We hypothesized that neck stiffness may impair laryngeal elevation (LE) in HNC patients and contribute to post-RT dysphagia. We evaluated the association between cervical stiffness and swallowing dysfunction after RT for HNC.</div></div><div><h3>Methods</h3><div>Ultrasound and swallowing function tests were conducted before and 6 months after RT for HNC. Stiffness of the sternocleidomastoid muscle (SM) was measured via shear wave elastography (SWE). To assess swallowing function comprehensively, videofluoroscopic swallowing studies were performed; based on these data, we calculated the Penetration–Aspiration Scale (PAS) score and quantified hyoid bone displacement and LE delay time.</div></div><div><h3>Results</h3><div>Of 29 patients, 8 showed post-RT dysphagia. Compared to prophylactic irradiation, a significant increase in neck stiffness was observed in the radical irradiation group (<em>p</em> = 0.018). Multivariable logistic regression analysis indicated that greater reductions in laryngeal elevation distance (LED) were significantly associated with post-RT dysphagia (OR: 0.67, 95 % CI: 0.47–1.10, <em>p</em> = 0.035).</div></div><div><h3>Conclusion</h3><div>SWE demonstrated a significant increase in neck stiffness following radiotherapy. Moreover, a greater reduction in LED was significantly associated with post-RT dysphagia, suggesting that impaired LE function may contribute to its development.</div></div>","PeriodicalId":55627,"journal":{"name":"Auris Nasus Larynx","volume":"52 6","pages":"Pages 796-802"},"PeriodicalIF":1.5,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145520390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}